{"denoms":[{"counts":[{"groupId":"BG000","value":"535"},{"groupId":"BG001","value":"541"},{"groupId":"BG002","value":"547"},{"groupId":"BG003","value":"1623"}],"units":"Participants"}],"groups":[{"description":"Participants ≤ 75 years old received 25 mg lenalidomide (R) administered by mouth (PO) on days 1 to 21 of each 28-day cycle plus 40 mg dexamethasone (d) PO on days 1, 8, 15, and 22 of a 28-day cycle until disease progression or intolerable toxicity. Participants \\> 75 years old received lenalidomide 25 mg PO on the same schedule and frequency plus 20 mg dexamethasone at the same schedule. Participants with moderate renal insufficiency received 10-15 mg lenalidomide (R) PO on days 1-21 of each 28-day treatment cycle and 20-40 mg dexamethasone (d) PO on days 1, 8, 15, and 22 of a 28-day cycle until disease progression or intolerable toxicity. Participants with severe renal insufficiency received 15 mg lenalidomide (R) PO every other day on days 1-21 of each 28-day treatment cycle and 20-40 mg dexamethasone (d) PO on days 1, 8, 15, and 22 of a 28-day cycle until disease progression or intolerable toxicity.","id":"BG000","title":"Lenalidomide and Low-Dose Dexamethasone (Rd)"},{"description":"Participants ≤ 75 years old received 25 mg lenalidomide (R) PO on days 1 to 21 of each 28-day treatment cycle 40 mg dexamethasone (d) PO on days 1, 8, 15, and 22 of a 28-day cycle for up to 18 cycles unless progressive disease (PD) or intolerable toxicity occurred. Those \\> 75 years old received lenalidomide 25 mg PO on the same schedule and frequency plus 20 mg dexamethasone (d) PO on days 1, 8, 15, and 22 of a 28-day cycle for up to 18 cycles unless PD or intolerable toxicity. Those with moderate renal insufficiency received 10-15 mg lenalidomide (R) PO on days 1-21 of each 28-day cycle and 20-40 mg dexamethasone (d) PO on days 1, 8, 15, and 22 of a 28-day cycle for up to 18 cycles unless PD or intolerable toxicity. Participants with severe renal insufficiency received 15 mg lenalidomide (R) PO every other day (QOD) on days 1-21 of each 28-day cycle and 20-40 mg dexamethasone (d) PO on days 1, 8, 15, and 22 of a 28-day cycle for up to 18 cycles unless PD or intolerable toxicity.","id":"BG001","title":"Lenalidomide and Dexamethasone Rd18"},{"description":"Participants received melphalan (M) 0.25 mg/kg PO daily (QD) on days 1 to 4 of each 42-day cycle plus prednisone (P) at 2 mg/kg PO on days 1 to 4 of each 42-day cycle and thalidomide 200 mg PO QD on days 1 to 41 of each 42-day cycle. MPT therapy was given for up to 12 cycles unless PD or intolerable toxicity occurred. Participants with moderate to severe renal insufficiency received melphalan (M) 0.10-0.125 mg/kg PO daily (QD) on days 1 to 4 of each 42-day cycle plus prednisone (P) at 2 mg/kg PO on days 1 to 4 of each 42-day cycle and thalidomide 100-200 mg PO QD on days 1 to 41 of each 42-day cycle. MPT therapy was given for up to 12 cycles unless PD or intolerable toxicity occurred.","id":"BG002","title":"Melphalan + Prednisone + Thalidomide (MPT)"},{"description":"Total of all reporting groups","id":"BG003","title":"Total"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"6.57","value":"73.2"},{"groupId":"BG001","spread":"6.50","value":"72.9"},{"groupId":"BG002","spread":"6.32","value":"73.1"},{"groupId":"BG003","spread":"6.46","value":"73.1"}]}]}],"dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","title":"Age, Continuous","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"241"},{"groupId":"BG001","value":"268"},{"groupId":"BG002","value":"260"},{"groupId":"BG003","value":"769"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"294"},{"groupId":"BG001","value":"273"},{"groupId":"BG002","value":"287"},{"groupId":"BG003","value":"854"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"40"},{"groupId":"BG001","value":"43"},{"groupId":"BG002","value":"44"},{"groupId":"BG003","value":"127"}]}],"title":"Asian"},{"categories":[{"measurements":[{"groupId":"BG000","value":"9"},{"groupId":"BG001","value":"6"},{"groupId":"BG002","value":"5"},{"groupId":"BG003","value":"20"}]}],"title":"Black or African American"},{"categories":[{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"1"},{"groupId":"BG003","value":"2"}]}],"title":"Native Hawaiian or other Pacific Islanders"},{"categories":[{"measurements":[{"groupId":"BG000","value":"474"},{"groupId":"BG001","value":"480"},{"groupId":"BG002","value":"491"},{"groupId":"BG003","value":"1445"}]}],"title":"White or Caucasian"},{"categories":[{"measurements":[{"groupId":"BG000","value":"6"},{"groupId":"BG001","value":"11"},{"groupId":"BG002","value":"3"},{"groupId":"BG003","value":"20"}]}],"title":"Other, Miscellaneous"},{"categories":[{"measurements":[{"groupId":"BG000","value":"5"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"3"},{"groupId":"BG003","value":"9"}]}],"title":"Undisclosed"}],"paramType":"NUMBER","title":"Race/Ethnicity, Customized","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"37"},{"groupId":"BG001","value":"33"},{"groupId":"BG002","value":"36"},{"groupId":"BG003","value":"106"}]}],"title":"Hispanic or Latino"},{"categories":[{"measurements":[{"groupId":"BG000","value":"493"},{"groupId":"BG001","value":"505"},{"groupId":"BG002","value":"508"},{"groupId":"BG003","value":"1506"}]}],"title":"Not Hispanic or Latino"},{"categories":[{"measurements":[{"groupId":"BG000","value":"5"},{"groupId":"BG001","value":"3"},{"groupId":"BG002","value":"3"},{"groupId":"BG003","value":"11"}]}],"title":"Undisclosed"}],"paramType":"NUMBER","title":"Race/Ethnicity, Customized","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"106"},{"groupId":"BG001","value":"106"},{"groupId":"BG002","value":"103"},{"groupId":"BG003","value":"315"}]}],"title":"Stage I"},{"categories":[{"measurements":[{"groupId":"BG000","value":"227"},{"groupId":"BG001","value":"229"},{"groupId":"BG002","value":"225"},{"groupId":"BG003","value":"681"}]}],"title":"Stage II"},{"categories":[{"measurements":[{"groupId":"BG000","value":"202"},{"groupId":"BG001","value":"206"},{"groupId":"BG002","value":"219"},{"groupId":"BG003","value":"627"}]}],"title":"Stage III"}],"description":"International Staging System (ISS) is used as a staging system for multiple myeloma and divides myeloma into 3 stages based only on the serum beta-2 microglobulin and serum albumin levels. Higher stages represent more advanced disease.","paramType":"NUMBER","title":"International Staging System (ISS)","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"155"},{"groupId":"BG001","value":"163"},{"groupId":"BG002","value":"156"},{"groupId":"BG003","value":"474"}]}],"title":"0 (fully active)"},{"categories":[{"measurements":[{"groupId":"BG000","value":"257"},{"groupId":"BG001","value":"263"},{"groupId":"BG002","value":"275"},{"groupId":"BG003","value":"795"}]}],"title":"1 (restrictive but ambulatory)"},{"categories":[{"measurements":[{"groupId":"BG000","value":"119"},{"groupId":"BG001","value":"113"},{"groupId":"BG002","value":"111"},{"groupId":"BG003","value":"343"}]}],"title":"2 (ambulatory but unable to work)"},{"categories":[{"measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"2"},{"groupId":"BG003","value":"6"}]}],"title":"3-4 (limited self-care, completely disabled)"},{"categories":[{"measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"3"},{"groupId":"BG003","value":"5"}]}],"title":"Missing"}],"description":"Eastern Cooperative Oncology Group (ECOG) Performance Status is used to assess the progress of disease in a patient, how the disease affects the daily living abilities of the patient, and determine appropriate treatment and prognosis.","paramType":"NUMBER","title":"Eastern Cooperative Oncology Group (ECOG) Performance Status","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"269"},{"groupId":"BG001","value":"280"},{"groupId":"BG002","value":"285"},{"groupId":"BG003","value":"834"}]}],"title":">=60 ml/min"},{"categories":[{"measurements":[{"groupId":"BG000","value":"266"},{"groupId":"BG001","value":"261"},{"groupId":"BG002","value":"261"},{"groupId":"BG003","value":"788"}]}],"title":"<60 ml/min"},{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"1"},{"groupId":"BG003","value":"1"}]}],"title":"Missing"}],"paramType":"NUMBER","title":"Creatinine clearance","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"224"},{"groupId":"BG001","value":"224"},{"groupId":"BG002","value":"234"},{"groupId":"BG003","value":"682"}]}],"title":">5.5 mg/L"},{"categories":[{"measurements":[{"groupId":"BG000","value":"309"},{"groupId":"BG001","value":"316"},{"groupId":"BG002","value":"312"},{"groupId":"BG003","value":"937"}]}],"title":"<=5.5 mg/L"},{"categories":[{"measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"1"},{"groupId":"BG003","value":"4"}]}],"title":"Missing"}],"paramType":"NUMBER","title":"Beta2 Microglobulin","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"192"},{"groupId":"BG001","value":"209"},{"groupId":"BG002","value":"223"},{"groupId":"BG003","value":"624"}]}],"title":"<=35 g/L"},{"categories":[{"measurements":[{"groupId":"BG000","value":"343"},{"groupId":"BG001","value":"331"},{"groupId":"BG002","value":"324"},{"groupId":"BG003","value":"998"}]}],"title":"> 35 g/L"},{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"1"}]}],"title":"Missing"}],"paramType":"NUMBER","title":"Albumin","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"448"},{"groupId":"BG001","value":"442"},{"groupId":"BG002","value":"434"},{"groupId":"BG003","value":"1324"}]}],"title":"<200 U/L"},{"categories":[{"measurements":[{"groupId":"BG000","value":"86"},{"groupId":"BG001","value":"99"},{"groupId":"BG002","value":"112"},{"groupId":"BG003","value":"297"}]}],"title":">=200 U/L"},{"categories":[{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"1"},{"groupId":"BG003","value":"2"}]}],"title":"Missing"}],"paramType":"NUMBER","title":"Lactic Dehydrogenase","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"138"},{"groupId":"BG001","value":"142"},{"groupId":"BG002","value":"123"},{"groupId":"BG003","value":"403"}]}],"title":"Immunoglobulin A"},{"categories":[{"measurements":[{"groupId":"BG000","value":"7"},{"groupId":"BG001","value":"6"},{"groupId":"BG002","value":"8"},{"groupId":"BG003","value":"21"}]}],"title":"Immunoglobulin A and Immunoglobulin G"},{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"1"},{"groupId":"BG003","value":"1"}]}],"title":"Immunoglobulin A and Immunoglobulin M"},{"categories":[{"measurements":[{"groupId":"BG000","value":"4"},{"groupId":"BG001","value":"7"},{"groupId":"BG002","value":"4"},{"groupId":"BG003","value":"15"}]}],"title":"Immunoglobulin D"},{"categories":[{"measurements":[{"groupId":"BG000","value":"334"},{"groupId":"BG001","value":"331"},{"groupId":"BG002","value":"350"},{"groupId":"BG003","value":"1015"}]}],"title":"Immunoglobulin G"},{"categories":[{"measurements":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"1"},{"groupId":"BG003","value":"5"}]}],"title":"Immunoglobulin M"},{"categories":[{"measurements":[{"groupId":"BG000","value":"49"},{"groupId":"BG001","value":"54"},{"groupId":"BG002","value":"60"},{"groupId":"BG003","value":"163"}]}],"title":"Not available (includes light-chain disease)"}],"paramType":"NUMBER","title":"Multiple Myeloma Subtype","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"170"},{"groupId":"BG001","value":"185"},{"groupId":"BG002","value":"189"},{"groupId":"BG003","value":"544"}]}],"title":"Adverse Risk"},{"categories":[{"measurements":[{"groupId":"BG000","value":"112"},{"groupId":"BG001","value":"103"},{"groupId":"BG002","value":"102"},{"groupId":"BG003","value":"317"}]}],"title":"Favorable Hyperdiploidy"},{"categories":[{"measurements":[{"groupId":"BG000","value":"148"},{"groupId":"BG001","value":"131"},{"groupId":"BG002","value":"141"},{"groupId":"BG003","value":"420"}]}],"title":"Normal"},{"categories":[{"measurements":[{"groupId":"BG000","value":"38"},{"groupId":"BG001","value":"56"},{"groupId":"BG002","value":"40"},{"groupId":"BG003","value":"134"}]}],"title":"Uncertain Risk"},{"categories":[{"measurements":[{"groupId":"BG000","value":"34"},{"groupId":"BG001","value":"35"},{"groupId":"BG002","value":"44"},{"groupId":"BG003","value":"113"}]}],"title":"Not evaluable"},{"categories":[{"measurements":[{"groupId":"BG000","value":"33"},{"groupId":"BG001","value":"31"},{"groupId":"BG002","value":"31"},{"groupId":"BG003","value":"95"}]}],"title":"Missing"}],"description":"Cytogenetic risk categories are mutually exclusive. Definitions: Adverse risk category: t(4:14), t(14:16), del (13q) or monosomy 13, del (17p), 1q gain; Non-adverse risk categories include favorable hyperdiploidy: t(11:14), gains of 5/9/15; normal: a normal result, gains other than 5/9/15, IgH deletion, and uncertain risk: probes used for analysis cannot place participant in any risk categories. Not evaluable: no specimen received, test failure or insufficient number of cells available for analysis.","paramType":"NUMBER","title":"Cytogenetic Risk","unitOfMeasure":"Participants"}],"populationDescription":"Intent to Treat (ITT) population includes all participants who were randomized, independent of whether they received study treatment or not"}